(Also on AXSM's advisory board)
Now given the choice to trust a world renown expert in the field, or a well meaning but confused blogger...
Here is one reply to his article: "It has no affinity to opioid receptors he’s completely confused on his molecules. It’s quite hilarious"...
First one on the list:
SCIENTIFIC ADVISORS
Maurizio Fava
Dr. Maurizio Fava is director, Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, executive vice chair of the Department of Psychiatry and executive director of the Clinical Trials Network and Institute, (MGH), and associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.
Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 900 original articles published in medical journals with international circulation. Dr. Fava's prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.
Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital's Depression Clinical and Research Program from 1990 until 2014. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.
Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals. He has developed with Dr. David Schoenfeld a novel design to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials. In 2009, Dr. Fava received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2013 the John T. Potts, Jr., MD Faculty Mentoring Award from Massachusetts General Hospital. He is also the former President of the American Society of Clinical Psychopharmacology.
Recent RLMD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:06:11 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 10:55:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:28:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:11:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:00:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:28:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 10:27:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:05:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:01:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 09:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 12:53:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:47:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 01:23:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:54:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:29:28 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM